CTOs on the Move

Karyopharm

www.karyopharm.com

 
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Thomas Murray
Director, Information Security and Privacy Profile

Similar Companies

Tenami Pharmaceuticals Inc

Tenami Pharmaceuticals Inc is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PACT Pharma

PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.

Lewis Drug

Lewis Drug is a Sioux Falls, SD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Control and Power Systems Inc

Control and Power Systems Inc is a Fairfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meridian Clinical Research

Meridian conducts clinical trials for drugs, vaccines, and more, but it starts with you — participation makes it all possible. See if youre eligible for a paid research study.